Avalo Therapeutics entered into an at-the-market (ATM) sales agreement with Jefferies LLC to establish a program for the potential issuance and sale of up to $200 million of common stock. Simultaneously, the company terminated its existing sales agreement with TD Securities (USA) LLC (formerly TD Cowen) that had been in place since June 2025.
Avalo Therapeutics reported its third quarter 2026 financial results, highlighting a cash position of $462.8 million which is expected to fund operations into 2029. The company is advancing its lead candidate, abdakibart, toward a Phase 3 program in hidradenitis suppurativa with initiation planned for the first half of 2027.
“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa. The efficacy and safety results observed across both dosing regimens, together with the potential for once-monthly administration, give us confidence in abdakibart’s potential to become an important new treatment option for patients with HS.”
Avalo Therapeutics reported its quarterly financial results for the period ended September 30, 2026, highlighting the continued clinical development of its lead immunology assets. The filing details research and development expenses, net losses, and the company's current liquidity position as it pursues key pipeline milestones.